Tag: Aquestive Therapeutics
Sublingual Epinephrine for Anaphylaxis Receives Fast Track Designation from FDA
AQST-109 is the first orally delivered epinephrine-based product candidate for the emergency treatment of allergic reactions including anaphylaxis.
CEO Expects Approval and Launch of Intranasal Emergency Epinephrine Spray by...
The market for epinephrine delivery may expand to include non-needle alternatives next year.
Aquestive’s Sublingual Epinephrine Achieves Therapeutic Blood Concentrations Following Administration
Company presented top level Phase 1 results at #AAAAI2022 meeting.
Sublingual Emergency Epinephrine Takes Another Step Forward in Phase 1 Study
Aquestive's postage-stamp-sized film is designed to dissolve under the tongue to provide epinephrine.
Aquestive Charts Ambitious Path Forward for Sublingual Emergency Epinephrine
Company updates the public on status of their candidate drug administered under the tongue.
Emergency Epinephrine Film Begins Phase 1 Clinical Trials
First healthy volunteer dosed in a Phase 1 study of AQST-108 for the treatment of allergic reactions including anaphylaxis.
Aquestive’s Sublingual Epinephrine Film Receives FDA Fast Track Designation for Treatment...
First planned PK clinical trial expected to begin during the third quarter of 2020.
Aquestive Files IND to Begin Clinical Trials of Sublingual Epinephrine
Epinephrine you slip under your tongue takes another step forward as the company submits their IND application.
FDA Opens Door for Clinical Development of Aquestive Therapeutics Anaphylaxis Treatment
Emergency epinephrine candidate dissolves in the mouth.
Update on Delivery of Emergency Epinephrine via Sublingual Film
Aquestive is finalizing the clinical trial application for a 2019Q2 study.
